neffy®, adrenaline nasal spray, now accessible on the Pharmaceutical Benefits Scheme for anaphylaxis
Palin Communications
Melbourne, 30 June 2026
CSL Seqirus, part of leading Australian biotechnology company CSL, has today welcomed the news that neffy® adrenaline (epinephrine) nasal spray will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1 July 2026, improving access for eligible Australians at risk of anaphylaxis. neffy is reimbursed for the emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over.1
Anaphylaxis occurs after exposure to an allergen, such as food, medications and insect bites and stings, and can be life threatening if not immediately treated with adrenaline. 2
Adrenaline rapidly reverses the effects of the condition by reducing throat swelling, opening the airways, and maintaining heart function and blood pressure and should be given without delay.2
Anaphylaxis rates have increased over recent decades.3
Australia has one of the highest documented rates of anaphylaxis hospital admissions in the developed world.4 Between 2015 and 2020, Australian public hospitals reported a 51% increase in emergency department presentations and a 35% increase in hospitalisations due to anaphylaxis.5,6
According to Professor Connie Katelaris AM, leading NSW allergist, the reimbursement of neffy is an important development for Australians who are at risk of anaphylaxis.
“Previously only available as private prescription, PBS listing of neffy gives more Australian patients the ability to access neffy should this be their preferred adrenaline device for the emergency treatment of anaphylaxis,” says Professor Katelaris.
“Anaphylaxis is a difficult condition to manage and the availability of subsidised adrenaline options means Australians living with anaphylaxis and their doctors have more choice in treatment options.”
Maria Said AM, Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia, says living with the risk of anaphylaxis can have a significant impact on the daily lives of Australians.
“For people who are at risk of anaphylaxis, everyday activities that many Australians take for granted often require careful planning and constant vigilance. Whether it's eating at restaurants, attending social events or travelling, those living with the risk of anaphylaxis are frequently thinking ahead about how to stay safe and what they would do in an emergency.
“For parents and carers of children at risk of anaphylaxis, experiences such as play dates, parties and school excursions require additional planning and preparation,” says Ms Said.
“People living with severe allergies know that there is no one-size-fits-all approach to managing anaphylaxis. The reimbursement of a treatment option that does not require injection provides patients with more choice to determine what may work best for them."
Associate Professor Kristina Rueter, Anaphylaxis Committee Chair of the Australasian Society of Clinical Immunology and Allergy (ASCIA), says healthcare professionals are being supported through updated clinical guidance and educational resources that now include neffy.
"ASCIA has updated its anaphylaxis guidelines, training modules and resources to include neffy, ensuring healthcare professionals have access to current information on available treatment options for anaphylaxis,” said Professor Rueter.
"Developed in consultation with allergy specialists and healthcare professionals, these updates aim to meaningfully support clinicians with practical, evidence-based resources around the management and treatment of anaphylaxis."
Claire Morgan, Senior Medical Director of Pharmaceuticals at CSL Seqirus, says the PBS listing is an important milestone in improving access and choice for Australians at risk of anaphylaxis.
"At CSL Seqirus, we are committed to improving access to medicines for Australian patients, and the PBS listing of this treatment option is an important milestone for people at risk of anaphylaxis,” says Ms Morgan.
"We are pleased that eligible Australians will now have subsidised access to this treatment option and acknowledge the valuable contribution of healthcare professionals, patient advocacy organisations and professional bodies in supporting the allergy community."
About neffy
neffy should be used at any signs or symptoms of anaphylaxis. After using adrenaline patients should seek emergency medical assistance immediately for close monitoring and in the event further treatment is required. neffy should not be withheld from anyone who is considered to need it. Anaphylaxis treatment options and management should be discussed with a patient’s clinician. neffy is a registered prescription medicine and can only prescribed by a doctor.
Side effects:7 All medicines can have side effects. Common side effects reported following neffy include headache, nasal discomfort, throat irritation and feeling jittery.
ENDS
MEDIA CONTACT
|
Palin Communications |
CSL Seqirus (+61) 0422 424 338 |
PBS Information (Authority Required): Refer to www.pbs.gov.au for full prescribing information and restrictions
Consumer Medical Information available at cslseqirus.com.au/products
About Anaphylaxis
Anaphylaxis is the most severe form of an allergic reaction and involves more than one body system, such as the skin, respiratory, gastrointestinal and cardiovascular systems.2
Symptoms include difficult or noisy breathing, swelling of the tongue, swelling or tightness in throat, wheeze or persistent cough, difficulty talking or hoarse voice, persistent dizziness or collapse. In young children it can also result in paleness and floppiness.2
About Allergy and Anaphylaxis Australia
Allergy & Anaphylaxis Australia is a registered charity and Australia’s only national patient support organisation, dedicated to helping i anyone in managing allergic disease. They work to raise awareness of allergic conditions in the community and provide credible, evidence-based information, resources and services to support Australians with allergic disease and those who care for them.
About Allergy250K
Allergy 250K provides age-appropriate information and resources to assist young people who are living with severe allergies, and to help them to feel more connected with other teens and young adults going through similar experiences in a fun but informative way.
About CSL Seqirus
CSL Seqirus is part of CSL Limited (ASX: CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
In Australia, CSL Seqirus operates the only local manufacturing facility for seasonal and pandemic influenza vaccine, and produces a range of unique medicines in the national interest, including antivenoms and the world’s only human vaccine for Q fever. Our commitment to Australia’s health also extends to providing access to paediatric and adult vaccines, and innovative pharmaceuticals for patients living with allergies, cardiovascular disease, severe pain, dry eye disease, iron deficiency, kidney and rare diseases.
Additional information
In relation to this CSL Seqirus media announcement, no honorarium was provided to Professor Connie Katelaris AM, Maria Said AM or Associate Professor Kristina Rueter. All have been briefed by CSL Seqirus on the TGA-approved use of this product.
For information on CSL products or to report an adverse event involving a CSL product, please contact CSL Seqirus on 1800 642 865.
neffy is distributed by Seqirus Pty Ltd ABN 26 160 735 035 655 Elizabeth Street Melbourne, Vic, 3000 Australia Telephone: 1800 642 865 www.cslseqirus.com.au
neffy is a registered trademark of ARS Pharmaceuticals Operations, Inc.
REFERENCES
- neffy Pharmaceutical Benefits Scheme Schedule.
- ASCIA. Anaphylaxis Fast Facts. Available at: https://www.allergy.org.au/patients/fast-facts/anaphylaxis. Accessed February 2026.
- Parliament of the Commonwealth of Australia. 2020. Available at: https://parlinfo.aph.gov.au/parlInfo/download/committees/reportrep/024422/toc_pdf/Walkingtheallergytightrope.pdf;fileType=application%2Fpdf. Accessed October 2025.
- Mullins RJ, et al. Clin Exp Allergy. 2016;46;1099–1110.
- Australian Commission on Safety and Quality in Health Care. 2021. Available at: https://www.safetyandquality.gov.au/standards/clinical-care-standards/acute-anaphylaxis-clinical-care-standard. Accessed October 2025.
- ASCIA. 2023. Available at: https://www.allergy.org.au/hp/papers/acute-management-of-anaphylaxis-guidelines. Accessed October 2025.
- neffy approved Consumer Medicine Information: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2025-CMI-02437-1&d=20251218172310101
CSL Seqirus is a CSL Limited company, ASX:CSL ABN: 26 260 735 035
Date approved: June 2026
AU-NEF-26-0093